Table 1.
Characteristics of mesenchymal stem cells (MSCs) in aplastic anemia (AA).
| Reference | N. of Patients | Main Findings |
|---|---|---|
| Lu S.H., et al. 2018 | - | Deficient or decreased expression of CD106 + MSCs accelerates bone marrow vascularization failure in AA patients |
| Deng S., et al. 2019 | - | The activation of VEGF–Notch pathway can restore the proliferation function of MSCs in AA patients |
| Li N., et al. 2020 | 3 | The microRNA miR-144-3p is involved in AA pathogenesis. Its targeting may be a therapeutic strategy |
| Li H., et al. 2017 | 15 | Bone marrow-derived MSCs modulate the levels of T-helper (Th)1, Th2, Th17, and T-regulatory cells, as well as their related cytokines in AA patients |
| Zhao J., et al. 2019 | - | Gingival-derived MSCs markedly improved survival and attenuated histological bone marrow damage in AA murine models |
| Li J., et al. 2012 | - | MSCs from AA patients show differential gene expression profiles associated with bone marrow failure |
| Huo J., et al. 2020 | 49 | MSCs from AA patients exhibited multifaceted defects in biological characteristics and alterative molecular genetics in the whole genome |
| Bueno C., et al. 2014 | - | MSC cultures from the bone marrow of AA patients display the same phenotype and differentiation potential as their counterparts from normal controls |